Antagonism of the Platelet-Activating Factor Pathway Mitigates Inflammatory Adverse Events Driven by Anti-erythrocyte Antibody Therapy in Mice.

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by low platelet counts primarily due to antiplatelet autoantibodies. Anti-D is a donor-derived polyclonal Ab against the rhesus D Ag on erythrocytes used to treat ITP. Unfortunately, adverse inflammatory/hypersensitivity reactions and a Food and Drug Administration-issued black box warning have limited its clinical use. This underscores the imperative to understand the inflammatory pathway associated with anti-erythrocyte Ab-based therapies. TER119 is an erythrocyte-specific Ab with anti-D-like therapeutic activity in murine ITP, while also exhibiting a distinct inflammatory signature involving production of CCL2, CCL5, and CXCL9 but not IFN-γ. Therefore, TER119 has been used to elucidate the potential mechanism underlying the adverse inflammatory activity associated with anti-erythrocyte Ab therapy in murine ITP. Prior work has demonstrated that TER119 administration is associated with a dramatic decrease in body temperature and inflammatory cytokine/chemokine production. The work presented in the current study demonstrates that inhibiting the highly inflammatory platelet-activating factor (PAF) pathway with PAF receptor antagonists prevents TER119-driven changes in body temperature and inhibits the production of the CCL2, CCL5, and CXCL9 inflammatory cytokines in CD-1 mice. Phagocytic cells and a functional TER119 Fc region were found to be necessary for TER119-induced body temperature changes and increases in CXCL9 and CCL2. Taken together, this work reveals the novel requirement of the PAF pathway in causing adverse inflammatory activity associated with anti-erythrocyte Ab therapy in a murine model and provides a strategy of mitigating these potential reactions without altering therapeutic activity.

Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP.

ABSTRACT: Fc gamma receptor (FcγR) IIIA is an important receptor for immunoglobulin G (IgG) and is involved in immune defense mechanisms as well as tissue destruction in some autoimmune diseases including immune thrombocytopenia (ITP). FcγRIIIA on macrophages can trigger phagocytosis of IgG-sensitized platelets, and prior pilot studies observed blockade of FcγRIIIA increased platelet counts in patients with ITP. Unfortunately, although blockade of FcγRIIIA in patients with ITP increased platelet counts, its engagement by the blocking antibody drove serious adverse inflammatory reactions. These adverse events were postulated to originate from the antibody's Fc and/or bivalent nature. The blockade of human FcγRIIIA in vivo with a monovalent construct lacking an active Fc region has not yet been achieved. To effectively block FcγRIIIA in vivo, we developed a high affinity monovalent single-chain variable fragment (scFv) that can bind and block human FcγRIIIA. This scFv (17C02) was expressed in 3 formats: a monovalent fusion protein with albumin, a 1-armed human IgG1 antibody, and a standard bivalent mouse (IgG2a) antibody. Both monovalent formats were effective in preventing phagocytosis of ITP serum-sensitized human platelets. In vivo studies using FcγR-humanized mice demonstrated that both monovalent therapeutics were also able to increase platelet counts. The monovalent albumin fusion protein did not have adverse event activity as assessed by changes in body temperature, whereas the 1-armed antibody induced some changes in body temperature even though the Fc region function was impaired by the Leu234Ala and Leu235Ala mutations. These data demonstrate that monovalent blockade of human FcγRIIIA in vivo can potentially be a therapeutic strategy for patients with ITP.

Neutralizing antibody response variation against dengue 3 strains.

To evaluate the neutralizing antibody activity of a human sera panel against seven strains of the homotypic virus. Sera were collected from DENV-3 immune individuals. Two DENV-3 genotypes and strains isolated at different time-points during the 2000 and 2001-2002 Havana epidemics were included. A panel of 20 late convalescent sera collected 16-18 months after acute illness from DF and DHF patients are studied. These individuals were infected during the 2001-2002 Havana DENV-3 epidemic. All but four sera collected from DF cases had a secondary DENV-1/DENV-3 infection. Sera neutralizing antibody titer against the seven DENV-3 strains were determined by plaque reduction neutralization technique. Sera samples were tested simultaneously. Studied sera showed higher levels of neutralizing antibodies to DENV-3 strains of genotype III compared to genotype V. Interesting, higher levels of neutralizing antibodies were detected to DENV-3 strain isolated at the end of the epidemic 2001-2002. An increased tendency of GMT of neutralizing antibodies according to epidemic evolution was observed for the 2001-2002 outbreak. In general, antibody levels in sera collected from DF cases were higher. Differences in the neutralization capacity of immune DENV-3 sera tested against two homologous genotypes including strains of the same genotype are demonstrated. Observed results suggest that virus changed in the course of the epidemic. The implications of this finding in terms of dengue pathogenesis and vaccine development need to be considered.

Secuencias de infección viral asociadas a la fiebre del dengue durante la epidemia de dengue 3 en la ciudad de La Habana, 2001-2002 / Viral infection sequences related to dengue fever in dengue 3 epidemics occurred in the City of Havana, 2001-2002

Objetivo: estudiar el papel de la infección secundaria y de la influencia de determinadas secuencias de infección virales en los casos de fiebre del dengue durante la epidemia de dengue 3, en la ciudad de La Habana, 2001-2002. Métodos: se estudiaron 141 muestras clínicas de casos confirmados de dengue en la epidemia cubana dengue 3. Todos los casos incluidos fueron clasificados de acuerdo con el criterio de la OMS como casos de fiebre del dengue, 101 de estas muestras fueron colectadas en la fase aguda de la enfermedad y 40 colectadas en la fase convaleciente tardía (16-18 meses después de la enfermedad). Resultados: los sueros colectados en la fase convaleciente tardía permitieron conocer las secuencias virales de infección, las cuales en orden descendiente fueron DEN-1/DEN-3, DEN-2/DEN-3 y DEN-1/DEN-2/DEN-3. Conclusiones: los resultados confirman que la secuencia de infección DEN-2/DEN-3 estuvo asociada a los casos de fiebre del dengue y no a los de fiebre hemorrágica del dengue; un porcentaje elevado de los casos estudiados se correspondió con una infección secundaria.

Objective: To study the role of secondary infection and of certain viral infection sequences in dengue fever cases during the dengue 3 epidemics occurred in the City of Havana. Methods: One hundred and forty one laboratory-confirmed clinical samples from dengue 3 cases were studied. According to WHO criteria, all included cases were classified as dengue fever cases; 101 of these samples were collected at the acute phase of the disease whereas 40 were collected in the late convalescence (16 to 18 months after the onset of disease). Results: The late convalescence serum samples allowed identifying the viral dengue infection sequences, which in downward order were DENV-1/DENV-3, DENV-2/DENV-3 and DENV-1/DENV-2/DENV-3. Conclusions: The results confirmed that the sequence infection DENV-2 / DENV-3 was associated with Dengue Fever Cases but not with the Dengue Hemorrhagic Fever Cases and that a high percentage of studied cases proved to be secondary infection.

Secuencias de infección viral asociadas a la fiebre del dengue durante la epidemia de dengue 3 en la ciudad de La Habana, 2001-2002 / Viral infection sequences related to dengue fever in dengue 3 epidemics occurred in the City of Havana, 2001-2002

Objetivo: estudiar el papel de la infección secundaria y de la influencia de determinadas secuencias de infección virales en los casos de fiebre del dengue durante la epidemia de dengue 3, en la ciudad de La Habana, 2001-2002. Métodos: se estudiaron 141 muestras clínicas de casos confirmados de dengue en la epidemia cubana dengue 3. Todos los casos incluidos fueron clasificados de acuerdo con el criterio de la OMS como casos de fiebre del dengue, 101 de estas muestras fueron colectadas en la fase aguda de la enfermedad y 40 colectadas en la fase convaleciente tardía (16-18 meses después de la enfermedad). Resultados: los sueros colectados en la fase convaleciente tardía permitieron conocer las secuencias virales de infección, las cuales en orden descendiente fueron DEN-1/DEN-3, DEN-2/DEN-3 y DEN-1/DEN-2/DEN-3. Conclusiones: los resultados confirman que la secuencia de infección DEN-2/DEN-3 estuvo asociada a los casos de fiebre del dengue y no a los de fiebre hemorrágica del dengue; un porcentaje elevado de los casos estudiados se correspondió con una infección secundaria(AU)

Objective: To study the role of secondary infection and of certain viral infection sequences in dengue fever cases during the dengue 3 epidemics occurred in the City of Havana. Methods: One hundred and forty one laboratory-confirmed clinical samples from dengue 3 cases were studied. According to WHO criteria, all included cases were classified as dengue fever cases; 101 of these samples were collected at the acute phase of the disease whereas 40 were collected in the late convalescence (16 to 18 months after the onset of disease). Results: The late convalescence serum samples allowed identifying the viral dengue infection sequences, which in downward order were DENV-1/DENV-3, DENV-2/DENV-3 and DENV-1/DENV-2/DENV-3. Conclusions: The results confirmed that the sequence infection DENV-2 / DENV-3 was associated with Dengue Fever Cases but not with the Dengue Hemorrhagic Fever Cases and that a high percentage of studied cases proved to be secondary infection(AU)